NEUBASE THERAPEUTICS INC (NBSE) Forecast, Price Target & Analyst Ratings
NASDAQ:NBSE • US64132K2015
0.378 USD
-0.01 (-3.2%)
At close: May 10, 2024
0.42 USD
+0.04 (+11.11%)
After Hours: 5/10/2024, 8:08:45 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEUBASE THERAPEUTICS INC (NBSE).
Forecast Snapshot
Consensus Price Target
$142.80
+ 37,677.78% Upside
Next Earnings Forecast
Release DateAug 12, 2024
ChartMill Buy Consensus
43.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$142.80
Upside
+ 37,677.78%
From current price of $0.38 to mean target of $142.80, Based on 6 analyst forecasts
Low
$141.40
Median
$142.80
High
$147.00
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
6 analysts have analysed NBSE and the average price target is 142.8 USD. This implies a price increase of 37677.78% is expected in the next year compared to the current price of 0.378.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
NBSE was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about NBSE.
In the previous month the buy percentage consensus was at a similar level.
NBSE was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-10-21 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-10-18 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022-10-17 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2022-08-12 | Chardan Capital | Maintains | Buy |
| 2022-05-31 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-13 | Chardan Capital | Maintains | Buy |
| 2021-06-01 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-12 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateAug 12, 2024
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | |||||||||
| EBITDA YoY % growth | -16.29M | -23.41M -43.71% | -22.61M 3.42% | -7.95M 64.84% | -25.38M -219.25% | -16.79M 33.85% | -26.17M -55.87% | -32.55M -24.38% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -17.47M | -24.59M -40.76% | -23.78M 3.29% | -9.07M 61.86% | -25.51M -181.26% | -17.07M 33.09% | -26.57M -55.65% | -33.32M -25.40% | N/A 57.12% | N/A -35.65% | N/A -31.58% | N/A 18.00% | N/A -21.95% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -10.60 | -16.80 -58.49% | N/A 30.79% | N/A | N/A | -0.89 96.58% | -0.92 -3.37% | -16.24 -1,665.22% | -7.30 55.05% | N/A -25.75% | N/A -26.67% | N/A 86.23% | N/A -17.83% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.21%
EPS Next 5 Year
14.88%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NEUBASE THERAPEUTICS INC / NBSE Forecast FAQ
What is the price target for NBSE stock?
6 analysts have analysed NBSE and the average price target is 142.8 USD. This implies a price increase of 37677.78% is expected in the next year compared to the current price of 0.378.
Can you provide the upcoming earnings date for NEUBASE THERAPEUTICS INC?
NEUBASE THERAPEUTICS INC (NBSE) will report earnings on 2024-08-12.
How do analysts rate NEUBASE THERAPEUTICS INC (NBSE)?
The consensus rating for NEUBASE THERAPEUTICS INC (NBSE) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.